Is sublingual immunotherapy ready for use in the United States?

JAMA

Volumn 309, Issue 12, 2013, Pages 1297-1298

  Nelson, Harold S ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOMODULATING AGENT; PLACEBO;

ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; EDITORIAL; HOME CARE; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SUBLINGUAL IMMUNOTHERAPY; TREATMENT DURATION; UNITED STATES; ASTHMA; DESENSITIZATION; METHODOLOGY; NOTE; PERENNIAL RHINITIS;

ASTHMA; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84875530805     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.2739     Document Type: Editorial

References (13)

1. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013;309(12):1278-1288.
2. Atkins D, Best D, Briss PA, et al GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
3. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66(6):740-752.
4. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011;41(9):1263-1272.
5. Nelson H, Blaiss M, Nolte H, Würtz SO, Andersen JS, Durham SR. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects. Allergy. 2013;68(2):252-255.
6. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338-1345. (Pubitemid 350225683)
7. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130(6):1327-1334, e1.
8. Larenas-Linnemann D, Cox LS; Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology. European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol. 2008;100(2):137-145. (Pubitemid 351238549)
9. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021-1035. (Pubitemid 44308083)
10. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802-809.
11. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126(5):969-975.
12. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725.
13. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(1):150-156, e1-e5.